AstraZeneca plc (LON:AZN) today announced that, with effect from 1 September 2019, Michel Demaré is appointed as a Non-Executive Director and a member of the Audit Committee. Leif Johansson, Chairman..

AstraZeneca plc (LON:AZN) today announced that the US Food and Drug Administration has granted Breakthrough Therapy Designation for Calquence as a monotherapy treatment for adult patients with chronic lymphocytic leukaemia,..

AstraZeneca plc (LON:AZN) and MSD Inc., known as Merck & Co., Inc. inside the US and Canada, today announced positive results from the Phase III PAOLA-1 trial in women with..

AstraZeneca plc (LON: AZN) today announced positive overall survival results from the Phase III FLAURA trial, a randomised, double-blinded, multi-centre trial of Tagrisso (osimertinib) in previously-untreated patients with locally-advanced or..

AstraZeneca plc (LON: AZN) and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced positive results from the Phase III..

AstraZeneca plc (LON:AZN) today announced that the European Commission has approved an update to the marketing authorisation for Forxiga to include positive cardiovascular outcomes and renal data from the Phase..

AstraZeneca plc (LON: AZN) today announced that the US Food and Drug Administration has issued a complete response letter regarding the supplemental New Drug Application for Farxiga (dapagliflozin) as an..

AstraZeneca (LON: AZN) has today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Imfinzi (durvalumab) for the treatment of small cell lung..

AstraZeneca plc (LON: AZN) has today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion to add a self-administration option..

AstraZeneca plc (LON: AZN) has today announced positive overall survival results from the Phase III CASPIAN trial with Imfinzi in 1st-line extensive-stage small cell lung cancer, a disease with significant..

AstraZeneca plc (LON:AZN) and MSD Inc., Kenilworth, N.J., US today announced that Lynparza has been approved in Japan as a maintenance treatment after 1st-line chemotherapy in patients with BRCA-mutated advanced..

AstraZeneca plc (LON:AZN) today announced that Bevespi Aerosphere has been approved in Japan as a fixed-dose, long-acting dual bronchodilator to relieve symptoms in patients with chronic obstructive pulmonary disease. This..

AstraZeneca plc (LON: AZN) and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) have today announced that the European Commission (EC)..

AstraZeneca plc (LON: AZN) has today announced detailed results from the interim analysis of the Phase III ASCEND trial at the European Hematology Association Annual Congress in Amsterdam, showing Calquence..

AstraZeneca plc (LON:AZN) today announced positive results from the Phase III ELEVATE-TN trial of Calquence(acalabrutinib) in patients with previously-untreated chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in..